Trial Profile
Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2023
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 13 Apr 2023 Status changed from recruiting to completed.
- 13 Jun 2017 New trial record